Drugs / MEDI5395
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03889275 | Oct 2019 → Nov 2021 | cancer | MedImmune LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEDI5395 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03889275 ↗ |
| Known as | NDV-GM-CSF | “Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV-GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors.” PMID 39551600 ↗ Nov 2024 |
| Route | Intravenous | “MEDI5395 was administered intravenously as six doses over 15-18 days.” PMID 39551600 ↗ Nov 2024 |